Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266745 | 0.84 | MPO (0.45) | DHFR | |
| SCHEMBL380792 | 0.83 | DHFR (0.67) | DHFR | |
| Water SCHEMBL28837029 | 0.81 | DHFR (0.65) | DHFR | |
| Hydrochloric Acid SCHEMBL8377343 | 0.81 | DHFR (0.65) | DHFR | |
| SCHEMBL21591751 | 0.78 | CHRNA7 (0.47) | — | |
| SCHEMBL9694096 | 0.75 | MPO (0.48) | — | |
| SCHEMBL1774870 | 0.75 | DHFR (0.69) | DHFR | |
| SCHEMBL6557271 | 0.75 | DHFR (0.59) | DHFR | |
| SCHEMBL7714720 | 0.75 | HRH4 (0.52) | — | |
| SCHEMBL27820723 | 0.74 | MMP2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104203939-A | Diaminopyrimidines as human Respiratory Syncytial Virus (RSV) inhibitors | ABBVIE INC | 2014-12-10 | — | — | CN | claimed |
| CN-105593215-B | 2, 4-or 4, 6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer | 安吉奥斯医药品有限公司 | 2019-01-15 | — | — | CN | disclosed |
| CN-104203939-A | Diaminopyrimidines as human Respiratory Syncytial Virus (RSV) inhibitors | ABBVIE INC | 2014-12-10 | — | — | CN | disclosed |
| CN-104024248-A | SERINE/THREONINE PAK1 INHIBITORS | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | DHFR 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.